[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lipid-metabolism-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lipid-metabolism-disorders":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,70,96,127,168,197],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100584962","effect-of-ilex-paraguariensis-harvest-time-and-consumption-method-of-processed-yerba-mate-on-the-lipid-profile-100584962",false,"NCT06896175","Effect of Ilex Paraguariensis Harvest Time and Consumption Method of Processed Yerba Mate on the Lipid Profile","Effect of Ilex Paraguariensis Harvest Time and Consumption Method of Processed Yerba Mate on the Lipid Profile of Consumes in the Department of Caaguazu, Paraguay","Inclusion Criteria:\n\n1. Individuals of both sexes, between 18 and 60 years of age, residing in the country, who consume prepared yerba mate.\n2. Consumers of mate or tereré and mate\u002Fterere who agree to consume the yerba mate samples provided by the research team, which will be masked from laboratory analysis.\n3. Two weeks of abstinence from consuming prepared yerba mate, either as mate or tereré, prior to randomization for the trial.\n4. Consume exclusively prepared yerba mate in the prescribed manner (quantity of yerba, frequency of consumption, and sips), either in its mate or tereré form independently, and for those who consume both forms daily.\n5. Do not change the yerba mate consumer's usual diet or regular physical activity during the trial period.\n6. Agree to know the laboratory results of the lipid profile only at the end of the trial (180 days after the start).\n\nExclusion Criteria:\n\n1. Individuals receiving lipid-lowering treatment at the start of the trial.\n2. Consuming any other type of yerba mate not provided by the principal investigator.\n3. Individuals requiring vitamins as a nutritional supplement.\n4. Individuals taking thermogenic supplements.\n5. Individuals consuming cooked mate.\n6. Addiction to medicinal plants or herbs, both mate and tereré.\n7. Individuals with a personal history of coronary artery disease.",true,"ALL","18 Years","60 Years",{"count":21,"type":22},198,"ESTIMATED","INTERVENTIONAL",[25],"NA","Introduction: This project studies the impact of Ilex paraguariensis harvest time, commonly known as yerba mate, and its consumption mode (mate, tereré, and mate\u002Fterere) on the lipid profile of consumers in the Department of Caaguazú, Paraguay. Yerba mate is rich in bioactive compounds such as polyphenols, xanthines, and saponins. There are no clinical trials conducted in Paraguay with our Ilex paraguariensis plantations that have analyzed the influence of harvest time on the yerba mate production process and the infusion mode, in relation to its effect on dyslipidemias. General Objective: To establish the effectiveness of Ilex paraguariensis harvest time and the mode of consumption of the produced yerba mate on the lipid profile of consumers in the Department of Caaguazú, Paraguay. Methodology: The research approach will be quantitative, using a triple-blind randomized clinical trial design. Participants will be regular consumers of yerba mate, divided into groups based on harvest time (beginning or end of the harvest) and consumption mode (mate, tereré, or both). Lipid profile measurements will be taken at baseline and at 30, 90, and 180 days after consumption. Yerba mate samples will be analyzed and classified according to their bioactive properties before being blinded to the researchers and participants. Expected results: a report on the social, cultural, and anthropometric characterization of regular consumers of mate and tereré, and a report on the concentrations of the bioactive properties of yerba mate; polyphenols, xanthines, saponins from Ilex paraguariensis harvested at the beginning and end of the harvest and the database of patients with baseline lipid profile results, at 30, 90, and 180 days of mate and tereré consumers with yerba mate prepared randomly according to the harvest time of the Ip (beginning or end of harvest) analyzed.",[28],"Lipid Metabolism Disorders","RECRUITING","2026-04-15",{"date":32,"type":33},"2026-04-16","ACTUAL",{"date":35,"type":33},"2026-02-01",{"date":37,"type":22},"2026-10-01",{"name":39,"class":40},"Universidad Nacional de Caaguazu","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100554084","early-phase-1-differential-thrombogenesis-by-epa-and-dha-mediated-by-hdl-100554084","NCT06494488","Differential Thrombogenesis by EPA and DHA Mediated by HDL","Differential Thrombogenesis Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Mediated by High-Density Lipoprotein (HDL)","Inclusion Criteria:\n\n* Fasting TG levels ≥ 150 mg\u002FdL and \\\u003C 500 mg\u002FdL and HDL-C ≤ 40 (men) or ≤ 50 (women)\n* LDL-C \\> 40 mg\u002FdL and ≤ 130 mg\u002FdL\n* Able to provide informed consent and adhere to study schedules\n* Agree to follow and maintain a relatively stable and low fatty fish intake diet (\\\u003C3 servings per week)\n\nExclusion Criteria:\n\n* Female with pregnancy, planned pregnancy (within the study period), or currently breastfeeding.\n* Subjects with weight changes greater than 20% over the past 3 months\n* Subjects planning a significant change in diet or exercise levels\n* Malabsorption syndrome and\u002For chronic diarrhea\n* Use of dietary supplements containing n-3 PUFA fatty acids\n* Frequent consumption of n-3 PUFA-enriched fish (\\>3 times a week)\n* Abnormal liver, kidney, or thyroid functions\n* Drug or alcohol abuse within 6 months or significant mental\u002Fpsychological impairment\n* Current smokers\n* Subjects taking daily aspirin, NSAIDs, anticoagulant, or corticosteroids\n* Subjects with known bleeding disorders (for example, hemophilia)\n* Known sensitivity or allergy to fish, shellfish, or omega-3 fatty acid supplements\n* Subjects requiring regular transfusions for any reason\n* No ethnic\u002Fracial groups will be excluded","69 Years",{"count":51,"type":22},80,[53],"EARLY_PHASE1","The goal of this study is to learn more about omega-3 polyunsaturated fatty acids supplementation on blood lipid profile and platelets in patients with high cholesterol levels.\n\nThe purpose of this research is to gather information on the safety and effect of two different fish oils, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\n\nParticipants will:\n\nVisit the clinic 3 times during study checkups, tests and blood collection. Randomized to either the EPA or the DHA supplementation group. Be given a 28-day food and activity log.",[28,56],"Hypertriglyceridemia",[58,59,60],"Fish oil","Atherogenic lipidemia","Lipoproteins","2025-09-25",{"date":63,"type":33},"2025-10-01",{"date":65,"type":33},"2025-07-10",{"date":67,"type":22},"2028-03-31",{"name":69,"class":40},"The Miriam Hospital",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":41},"100596645","perfect-heartio-drink-and-cardiovascular-health-100596645","NCT07048158","\"Perfect Heartio\" Drink and Cardiovascular Health","Beneficial Effects of \"Perfect Heartio\" Drink in Improving Cardiovascular Health","Inclusion Criteria:\n\n* General healthy subjects during enrolment\n* Age 18 and above\n* Willing to comply with interventional plan and comes to do follow up\n* Willing to gives consent\n\nExclusion Criteria:\n\n* Use nonsteroidal anti-inflammatory drugs (NSAIDs) more than once a week during enrolment\n* Use of anticoagulants or corticosteroids\n* Use of individual supplements of vitamin A, E, or beta carotene more than once a week during enrolment\n* Renal failure or dialysis, cirrhosis, other serious conditions that precluded participation\n* No previous history of cancer (except nonmelanoma skin cancer)\n* Pregnant or lactating woman",{"count":78,"type":22},55,[25],"Noncommunicable diseases (NCDs) such as type 2 diabetes (T2D) and cardiovascular disease (CVD) account for more deaths globally than any other condition. In 2018, the WHO reported that NCDs accounted for 71% of global deaths. They also showed that low- and middle-income countries are disproportionately affected by NCDs, accounting for 85% of NCD-related deaths among individuals aged 30-69 y. Among NCDs, CVD is the leading and fourth-leading causes of death, accounting for 19.5 million deaths worldwide in 2018. Furthermore, despite increasing global awareness, the prevalence of these conditions continues to increase at alarming rates. Deaths from CVD are expected to reach 23.6 million annually by 2030 from 17.6 million deaths in 2016. The underlying aetiology of these conditions is complex, as they can be influenced by several environmental, genetic, and behavioural factors. However, diet and nutrition play a particularly important role in these conditions, especially in the context of the double burden of malnutrition facing many low- and middle-income countries.",[82,28],"Cardiovascular Diseases",[84,85],"Complementary and alternative medicine","Herbal Medicine","2025-07-02",{"date":88,"type":33},"2025-07-08",{"date":90,"type":33},"2025-04-01",{"date":92,"type":22},"2025-12-31",{"name":94,"class":95},"The Perfect Series Sdn Bhd","INDUSTRY",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":113,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":41},"100583627","postprandial-metabolome-and-metabolic-flexibility-100583627","NCT06878781","Postprandial Metabolome and Metabolic Flexibility","Standardized Meals With Different Macronutrient Ratios on the Postprandial Metabolome and Metabolic Flexibility","Inclusion Criteria:\n\n* be over 18 years of age and under 30 years of age;\n* without active drug addictions: smoking, alcoholism, and\u002For drug addiction;\n* in female subjects: regular menstrual cycles;\n* give written consent for their inclusion in the study.\n\nExclusion Criteria:\n\n* subjects with any pathology that requires medication or special treatment, such as type 2 diabetes mellitus, high blood pressure, dyslipidemia, polycystic ovary syn-drome, autoimmune, thyroid, kidney, neurological diseases, and cancer;\n* pregnant or lactating women;\n* subjects with problems with chewing, salivation, and swallowing.\n\nElimination criteria:\n\n* subjects who only have samples (blood and calorimetry) from one study period (fasting or postprandial);\n* subjects who only have samples (blood and calorimetry) of a metabolic challenge;\n* subjects who have an infection at the scheduled appointment;\n* subjects who withdraw their informed consent","30 Years",{"count":105,"type":22},300,[25],"Metabolic flexibility is a process in which the body can switch energy substrates in different physiological states. This flexibility plays an important role in an individual's health because losing it increases the risk of obesity, metabolic syndrome, insulin resistance, and type 2 diabetes. Considering that humans spend most of their awakening hours in a postprandial (PP) state, an organism's metabolic flexibility (MF) to respond to a standardized meal's consumption would provide information on the individual's metabolic health. The PP response to glucose following an oral glucose tolerance test or consumption of a high-carbohydrate meal is well described; however, few studies assess the FM and PP metabolome using mixed meals with different macronutrients. The investigators address how metabolic flexibility and metabolome change after consuming standardized meals with different macronutrient ratios. Data collection includes clinical and diet information, indirect calorimetry, and capillary blood sampling during fasting and after consumption of standardized meals. Samples are collected weekly for one month. The data will determine the metabolic flexibility and metabolome after consuming standardized meals with different macronutrient ratios.",[109,110,28,111,112],"Fasting","Postprandial Hyperglycemia","Glucose Metabolism Disorders","Insulin Sensitivity",[114,115,116],"metabolic flexibility","postprandial response","mixed meals","2025-03-10",{"date":119,"type":33},"2025-03-17",{"date":121,"type":33},"2024-01-08",{"date":123,"type":22},"2026-12-18",{"name":125,"class":126},"Instituto Nacional de Medicina Genomica","OTHER_GOV",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":16,"sex":135,"minAge":4,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":141,"conditions":142,"keywords":149,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":41},"100582190","phase-1-impact-of-chromium-supplementation-on-glucido-lipidic-metabolism-oxidative-stress-and-inflammatory-state-in-patients-with-gestational-diabetes-100582190","NCT06860087","Impact of Chromium Supplementation on Glucido-lipidic Metabolism, Oxidative Stress and Inflammatory State in Patients with Gestational Diabetes","Impact of Chromium Supplementation on Glucido-lipidic Metabolism, Oxidative Stress and Inflammatory State in Pregnant Women with Gestational Diabetes Mellitus","Cr and GDM","Inclusion Criteria:\n\n* Healthy pregnant women:\n\n  * Whose their gestational age is 28 weeks\n  * They have no pathology or complication associated with their pregnancy.\n* Pregnant women with gestational diabetes mellitus:\n\n  * They will be selected according to the criteria of the one-step method for screening for gestational diabetes mellitus established by the WHO.\n  * They have no other pathology or complication associated with pregnancy.\n  * They are subjected to insulin therapy and a low-calorie diet, rich in protein, fiber and beneficial lipids (they will all asked to keep their medical treatment prescribed by their doctor).\n* All women involved in this study will be systematically supplemented with 60 mg\u002Fd iron and 400 mg\u002Fd vitamin B9 during pregnancy as recommended by WHO.\n\nExclusion Criteria:\n\n* Pregnant women with unrecognized diabetes, type I or type II, will not be involved in this study.\n* Pregnant women who were supplemented before one month or during pregnancy, or who will need other micronutrient supplements during the study to avoid their influence on the results.\n* Pregnant women who develop other health complications will be removed from the study and replaced by others.\n* Women with gestational diabetes mellitus who were unable to complete chromium supplementation up to 6 weeks will be excluded from the study and replaced by others.","FEMALE",{"count":137,"type":22},200,[139,140],"PHASE1","PHASE2","Our study aims to explore the influence of dietary chromium supplementation in the form of chromium picolinate, at different doses (200 µg and 400 µg per day), on the health of pregnant women with gestational diabetes. This study will also provide more information on the safety of this type of supplementation during pregnancies complicated by gestational diabetes mellitus.\n\nThe main questions it aims to answer are:\n\n* Does chromium supplementation at various doses in women with gestational diabetes mellitus truly influence their glucido-lipidic metabolism, oxidative\u002Fantioxidant balance, and inflammatory state? If so, is it beneficial or detrimental?\n* If this supplementation is beneficial, which dose is the most appropriate?\n* Do these types of supplementation have any side effects on the health of the mother and fetus? The participants will take chromium supplements for 6 weeks (supplemented groups) while the control participants will not take them (healthy and diabetic control groups).\n\nChromium-supplemented participants will undergo a medical check-up every 02 weeks to closely monitor their health status and detect any potential side effects at an early stage.\n\nResearchers will compare the biochemical profile, oxidative stress status, and inflammation markers between chromium-supplemented and non-supplemented participants to assess the impact of this trace element.\n\nResearchers will compare the effects of chromium supplements at different doses with each other.",[143,144,145,146,147,148,28],"Gestational Diabetes Mellitus (GDM)","Oxidative Stress","Inflammatory Status","Insulin Resistance","Leptin Resistance","Glucose Metabolism Disorder",[150,151,152,153,154,155,156,157],"Inflammatory status markers","Oxidative stress markers","Glucido-lipidic metabolism","HOMA-IR","Leptin level","Lipid profile","Fasting plasma glucose","Insulin level","NOT_YET_RECRUITING","2025-03-01",{"date":161,"type":33},"2025-03-05",{"date":163,"type":22},"2025-05",{"date":165,"type":22},"2026-01",{"name":167,"class":40},"University of Kasdi Merbah",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":184,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":41},"100564203","efficacy-of-lipid-lowering-therapy-based-on-apolipoprotein-b-versus-ldl-cholesterol-levels-in-patients-undergoing-percutaneous-coronary-intervention-100564203","NCT06626126","Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention","Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention: a Multicenter, Randomized Controlled Trial","ApoB-guidedLLT","Inclusion Criteria:\n\n1. Patients aged 18 years or older.\n2. Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).\n3. Patients who agree to participate and provide informed consent.\n\nExclusion Criteria:\n\n1. Inability to Provide Informed Consent: Patients who are unable or unwilling to provide consent.\n2. Limited life expectancy: patients with a life expectancy of less than 12 months due to other non-cardiac conditions.\n3. Liver Disease: patients with cirrhosis or significant liver dysfunction.\n4. Patients with contraindication to statin or other lipid-lowering therapy.\n5. Any condition that may interfere with the study process, including treatment adherence or follow-up appointments (e.g., dementia, alcohol abuse, severe debilitation, long distances required for follow-up, etc.).",{"count":177,"type":22},1448,[25],"This multicenter randomized trial is designed to assess the efficacy of lipid-lowering therapy in patients undergoing percutaneous coronary intervention, comparing an Apolipoprotein B-targeted approach with a Low-Density Lipoprotein Cholesterol (LDL-C)-targeted approach. The primary outcomes are to evaluate the proportion of patients achieving lipid-lowering treatment goals at the 1-year follow-up between the two treatment strategies: Apolipoprotein B-based therapy versus LDL-C-based therapy.",[181,182,183,28],"Coronary Arterial Disease (CAD)","Percutaneous Coronary Intervention","LDL-cholesterol",[174,185,186,187],"PCI","Coronary artery disease","lipid lowering therapy","2024-10-13",{"date":190,"type":33},"2024-10-16",{"date":192,"type":22},"2025-01-01",{"date":194,"type":22},"2029-01-01",{"name":196,"class":40},"University Medical Center Ho Chi Minh City (UMC)",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":205,"enrollmentInfo":206,"targetDuration":208,"studyType":209,"phases":4,"briefSummary":210,"conditions":211,"keywords":214,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":41},"100545538","cardiovascular-renal-adverse-prognosis-assessment-system-for-coronary-heart-disease-with-chronic-kidney-disease-based-on-metabolomics-100545538","NCT06383208","Cardiovascular-Renal Adverse Prognosis Assessment System for Coronary Heart Disease With Chronic Kidney Disease Based on Metabolomics","Cardiovascular-Renal Adverse oUtcome rIsk aSsessment systEm for Coronary Heart Disease Complicated With Chronic Kidney Disease Based on Targeted Lipid METabolomics","CRUISE-MET","Inclusion Criteria:\n\n1. Age 18-80 years old;\n2. Diagnosed with CHD during hospitalization through coronary angiography, including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation acute coronary syndrome (NST-ACS), stable angina pectoris;\n3. Patients with clarified renal function status.;\n\nCKD is defined as meeting one of the following criteria, with a duration of more than 3 months: eGFR \\\u003C 60 ml\u002Fmin\u002F1.73 m² or eGFR ≥ 60 ml\u002Fmin\u002F1.73 m² and urinary albumin-to-creatinine ratio (uACR) ≥ 30 mg\u002Fg;\n\nExclusion Criteria:\n\n1. Pregnancy or lactation;\n2. Severe valve disease or severe mechanical complications requiring surgical intervention;\n3. Severe psychiatric illness or other reasons that impede follow-up compliance;\n4. Severe hematologic disorders or end-stage malignant tumors;\n5. Having undergone kidney transplantation or long-term maintenance dialysis;\n6. Severe liver disease (Child-Pugh class C);\n7. Received acute renal failure dialysis treatment within 12 weeks prior to screening for enrollment;\n8. Severe chronic lung disease requiring long-term mechanical ventilation support or awaiting lung transplantation;\n9. Life expectancy less than 1 year.","80 Years",{"count":207,"type":22},470,"12 Months","OBSERVATIONAL","Coronary heart disease (CHD) combined with chronic kidney disease (CKD) affects a substantial portion of the population and carries a significant disease burden, often leading to poor outcomes. Despite efforts to strictly control traditional risk factors, the efficacy in improving outcomes for patients with both CHD and CKD has been limited. Recent advancements in lipid metabolism research have identified new lipid metabolites associated with the occurrence and prognosis of CHD and CKD. Our preliminary trial has shown that levels of certain lipid metabolites, such as Cer(18:1\u002F16:0), HexCer(18:1\u002F16:0), and PI(18:0\u002F18:1), are notably elevated in patients with CHD and reduced kidney function compared to those with relatively normal kidney function. This suggests that dysregulation of these non-traditional lipid metabolites may contribute to residual risk for adverse outcomes in these patients.\n\nFurthermore, the emerging concept of \"cardiovascular-kidney-metabolic syndrome\" and the availability of new treatment options highlight the urgent need for a risk stratification tool tailored to modern management strategies and treatment goals to guide preventive measures effectively. To address this, we propose to conduct a prospective cohort study focusing on CHD combined with CKD. This study aims to comprehensively understand the clinical characteristics, diagnosis, treatment status, and cardiovascular-kidney prognosis in these patients. Through advanced metabolomics analysis, we seek to identify lipid metabolism profiles and non-traditional lipid metabolites associated with the progression of coronary artery disease in CHD-CKD patients. Leveraging clinical databases and metabolomics data, we will develop a robust risk prediction model for adverse cardiovascular-kidney outcomes, providing valuable guidance for clinical diagnosis, treatment decisions, and ultimately improving patient prognosis.",[212,213,28],"Chronic Kidney Diseases","Coronary Heart Disease",[212,213,28,215,216],"Cardiovascular-Renal adverse prognosis","Metabolomics","2024-04-21",{"date":219,"type":33},"2024-04-25",{"date":221,"type":33},"2024-04-01",{"date":223,"type":22},"2027-03-31",{"name":225,"class":40},"China-Japan Friendship Hospital"]